(1 - 10 von 16
)
Merck KGaA starts mid-stage multiple-sclerosis trial - Reuters
www.reuters.com
— ... mode of action and convenient administration,” said Anton Hoos, head of global development at Merck Serono, the drug arm of Merck KGaA. › article
ZymoGenetics and Merck Serono Initiate Phase 2/3 Clinical Trial of...
www.finanznachrichten.de
Anton Hoos, M.D., Merck Serono's Head of Global Development, added: “This study forms part of our ongoing development program with atacicept ...
Cetuximab ups survival rate in head and neck cancer: Study
test.pharmabiz.com
... were published in the New England Journal of Medicine in 2006," said Dr Anton Hoos, executive vice president, Global Development, Merck Serono. › news
German Merck KGaA starts mid-stage lupus trial | Reuters
www.reuters.com
"Atacicept has the potential to alter the course of SLE, a complex and devastating disease," said Anton Hoos, Merck Serono's head of global development, in a
sortiert nach Relevanz / Datum